Clinical Investigation of Omega Refractive Capsule, Model VI

Cataract Clinical Trial

— ORCVI  

Official title:

Clinical Investigation of Omega Refractive Capsule, Model VI in Combination With a Commercially Available, FDA Approved Monofocal or Toric Intraocular Lens

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04574115
• Other study ID #: Omega Refractive Capsule VI
• Status: Active, not recruiting
• Phase: N/A
• Start date: February 6, 2021
• Est. completion date: June 2024

Study information

• Verified date: March 2023
• Source: Omega Ophthalmics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to evaluate the safety and effectiveness of the investigational Omega Refractive Capsule (model VI)

Description:

This study is a prospective, interventional, randomized, controlled, paired eye, subject-masked design.

Subjects will be randomly assigned to which eye will receive the Omega Refractive capsule VI with an FDA approved intraocular lens. Fellow eyes will serve as controls and receive an FDA approved IOL (no Omega capsule).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 30
• Est. completion date: June 2024
• Est. primary completion date: June 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• 40 years of age or older at the time of surgery diagnosed with bilateral cataracts

• Able to understand and sign an informed consent

• Willing and able to complete all study visits and assessments required for the study

• Calculated lens power within the available range

• Corrected distance visual acuity is equal to or worse than 20/40 in each eye with or without a glare source present

• Bilateral cataracts eligible for extraction by phacoemulsification and capsular bag fixated IOL implantation

• Potential postop visual acuity of 20/25 or better in the judgment of the surgeon

• Preoperative corneal astigmatism of 4.0 D or less with normal corneal topography

• Clear intraocular media other than cataract

• Preop endothelial cell density of 2000 cells/mm2 or more

Exclusion Criteria:

• Subject's best corrected vision is light perception or no light perception in either eye

• Cataract opacification preventing adequate Binocular Indirect Ophthalmoscopic retinal and macular examination.

• Orbital abnormalities, such as thyroid related orbitopathy, causing significant exophthalmos.

• Eyelid abnormalities causing lagophthalmos.

• Significant anterior blepharitis or meibomian gland dysfunction

• Corneal abnormalities or conditions, other than regular topographic corneal astigmatism

• Krukenburg's spindle (linear pigmentary deposits on the corneal endothelium)

• Abnormalities of the iris including trans-illumination defects

• Pupil abnormalities (abnormally shaped, fixed or non-reactive)

• Pharmacologic dilation less than 7 mm

• Axial length <22.5mm

• Lens thickness <4.1 mm

• Anterior chamber depth <2.5mm

• Prior ocular surgery

• Epiretinal membrane

• Macular edema

• Retinal tears including operculated holes

• Amblyopia

• Glaucoma of any kind

• Pseudoexfoliation syndrome

• History of uveitis/iritis

• Diabetic retinopathy

• Acute, chronic or uncontrolled systemic or ocular disease that may confound the results of the study (including rheumatologic conditions such as Rheumatoid arthritis, ankylosing spondyliltis, Sjögren's syndrome, and neurologic conditions such as optic neuritis or multiple sclerosis).

• Prior or anticipated use of tamsulosin or silodosin (e.g., Flomax®, Flomaxtra®, Rapaflo®) or similar medications

• Average Keratometry <38D or > 48D by topography

• Any pathology of the zonules including evidence of zonular weakness, zonular instability, zonular damage, or coloboma effecting zonules.

• History of ocular trauma

• Pregnant, lactating, or has another condition with associated fluctuation of hormones that could lead to refractive changes

Related Conditions & MeSH terms

• Cataract

Intervention

Device:
• Omega Refractive Capsule with an FDA approved Intraocular Lens
Omega refractive capsule in conjunction with an FDA approved Intraocular Lens
• FDA approved Intraocular Lens
FDA approved Intraocular Lens

Locations

Country	Name	City	State
Costa Rica	Clinica 20/20	San José

Sponsors (1)

Lead Sponsor	Collaborator
Omega Ophthalmics

Country where clinical trial is conducted

Costa Rica, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Absence of fusion of peripheral anterior and posterior capsule	slit lamp exam assessment	6 Month Postoperative Visit